Category Archives: HIV care & treatment

Project Inform Helps to Lead San Francisco’s Effort to Get to Zero

Logo G2Z

The United States is making significant progress nationally in strengthening the health outcomes of people living with HIV and AIDS and reducing new cases of HIV infection. Much of that progress has to do with the strength of the arsenal of HIV medications that exists today;…Read More

Sexual Transmission of HCV: News from the AASLD Liver Meeting, November 2015

Logo AASLD_sm

Sexual transmission of HCV is a poorly understood issue that leads to much confusion among patients and providers. It is widely accepted that people living with HIV are at greater risk of sexual transmission of HCV, but the way in which this happens is poorly understood….Read More

HIV cure advocates publish guide to cure science terminology

post_glossarysm

CLICK HERE to order a copy of the HIV/AIDS Cure Research Glossary To better inform journalists, service workers, advocates and people with HIV on the exciting and rapidly moving field of HIV cure research, advocates from the Delaney AIDS Research Enterprise (DARE), with assistance from advocates…Read More

Project Inform announces new 2016 Covered CA Plan Guide & Formulary analysis

Project Inform and several other community partners today released the guide, “How to Choose a Health Plan in Covered California”, for people living with HIV and/or hepatitis C (HCV) and individuals considering pre-exposure prophylaxis (PrEP). The guide explains important things to consider when choosing a plan…Read More

FDA approves new treatment for HIV

From an FDA press release … On November 5, the U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years…Read More

IAS2015: Maintenance HIV regimen of rilpivirine and boosted darunavir as effective as three-drug treatment in early results

post_2015IAS_sm

A presentation at the 2015 International AIDS Society conference in Vancouver reported 24-week results comparing a maintenance regimen of rilpivirine (Edurant) + boosted darunavir (Prezista/ritonavir) to a three-drug regimen of a boosted protease inhibitor and two NRTIs. This could offer some people a new treatment option should…Read More

IAS2015: START study confirms the benefits of starting HIV treatment at any CD4 count

post_2015IAS_sm

by Alan McCord, Director of Education A presentation at the 2015 International AIDS Society conference in Vancouver reported additional results from the START (Strategic Timing of Antiretroviral Treatment) Study that showed significant benefits to starting HIV treatment earlier rather than waiting until later to start: a 57%…Read More